Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Crosses Above 200 Day Moving Average – Time to Sell?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $10.76 and traded as high as $11.19. Zevra Therapeutics shares last traded at $11.17, with a volume of 2,064,533 shares changing hands.

Key Zevra Therapeutics News

Here are the key news stories impacting Zevra Therapeutics this week:

  • Positive Sentiment: HC Wainwright increased its EPS estimates for Q4 2026 to $0.14 from $0.13, FY2026 to $0.91 from $0.68, and FY2027 to $0.66 from $0.55. It also lifted estimates for FY2028–FY2030 and retained a Buy rating with a $26 target. The upward revisions point to improved analyst expectations for future earnings.
  • Positive Sentiment: Cantor Fitzgerald kept its Buy rating on Zevra Therapeutics, reinforcing the positive analyst outlook. Cantor Fitzgerald Keeps Their Buy Rating on Zevra Therapeutics
  • Positive Sentiment: BTIG also gave Zevra a Buy rating, adding to the favorable analyst sentiment. Zevra Therapeutics Receives a Buy from BTIG

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ZVRA shares. Canaccord Genuity Group lowered their price objective on shares of Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, July 27th. Weiss Ratings reissued a “hold (c)” rating on shares of Zevra Therapeutics in a research note on Wednesday, August 19th. William Blair raised shares of Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. Citizens Jmp raised their target price on shares of Zevra Therapeutics from $25.00 to $28.00 and gave the stock a “market outperform” rating in a report on Thursday, August 6th. Finally, UBS Group restated a “buy” rating on shares of Zevra Therapeutics in a research report on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, Zevra Therapeutics has an average rating of “Buy” and an average target price of $27.14.

Read Our Latest Report on Zevra Therapeutics

Zevra Therapeutics Trading Up 10.1%

The stock has a market cap of $688.21 million, a price-to-earnings ratio of 6.39 and a beta of 1.01. The company has a fifty day simple moving average of $11.07 and a 200-day simple moving average of $10.78.

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last announced its earnings results on Tuesday, November 3rd. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.16 by $0.10. The company had revenue of $37.76 million during the quarter, compared to analysts’ expectations of $37.08 million. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 54.54%. As a group, analysts anticipate that Zevra Therapeutics, Inc. will post 0.87 earnings per share for the current year.

Insider Buying and Selling

In other Zevra Therapeutics news, CEO Neil McFarlane sold 20,000 shares of Zevra Therapeutics stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $11.25, for a total transaction of $225,000.00. Following the transaction, the chief executive officer directly owned 417,225 shares in the company, valued at approximately $4,693,781.25. The trade was a 4.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Corey Watton sold 12,300 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $11.25, for a total value of $138,375.00. Following the completion of the sale, the director owned 1,800 shares of the company’s stock, valued at $20,250. The trade was a 87.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 3.70% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. AIGH Capital Management LLC purchased a new position in Zevra Therapeutics during the first quarter valued at approximately $11,184,000. Integrity Alliance LLC. acquired a new position in Zevra Therapeutics in the 3rd quarter valued at approximately $10,292,000. Hennion & Walsh Asset Management Inc. increased its stake in Zevra Therapeutics by 116.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company’s stock valued at $5,502,000 after buying an additional 206,543 shares during the period. Dimensional Fund Advisors LP lifted its position in Zevra Therapeutics by 259.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock worth $5,168,000 after buying an additional 400,336 shares in the last quarter. Finally, Mystic Asset Management Inc. lifted its position in Zevra Therapeutics by 0.9% in the 3rd quarter. Mystic Asset Management Inc. now owns 355,380 shares of the company’s stock worth $3,899,000 after buying an additional 3,270 shares in the last quarter. 35.03% of the stock is owned by institutional investors and hedge funds.

About Zevra Therapeutics

(Get Free Report)

Zevra Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company combines traditional drug development with data science and patient-focused research to advance therapies for diseases that may have limited treatment options.

Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which is approved in the United States for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and children aged 2 years and older, in combination with miglustat.

Featured Stories

Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.